Outlook Therapeutics® to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference
ISELIN, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics, will participate in a panel discussion titled, “Take A Look At What's In Store For Wet AMD & Related Diabetic Eye Diseases,” at the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference on Thursday, December 8, 2022 at 2:45 PM ET.
In addition to the panel presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
The panel discussion is open to thos who are registered to attend the event. Please contact your Cantor representative for more information.
About Outlook Therapeutics, Inc.
What Do Businesses Need for Effective Communication and Collaboration in Today's Work Environment?
Solutions Showcase TBA
Conference Luncheon - For Diamond, Platinum, Super Pass, Exhibitor/Conference, Speaker, Press Pass Holders